EG 005
Alternative Names: EG005Latest Information Update: 09 Mar 2007
At a glance
- Originator Unknown
- Class Small molecules
- Mechanism of Action Angiotensin receptor antagonists; Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Lipodystrophy
Most Recent Events
- 07 Mar 2007 Discontinued - Phase-II for Lipodystrophy in United Kingdom (PO)
- 05 Sep 2006 Initial results from a extension study of a phase II trial in lipodystrophy have been added to the Cancer therapeutic trials section
- 30 Aug 2006 Ark Therapeutics has completed a 1-year voluntary extension study of a phase II trial in lipodystrophy in the UK